AR122323A1 - Compuesto de niclosamida, composición que lo comprende y cocristal - Google Patents
Compuesto de niclosamida, composición que lo comprende y cocristalInfo
- Publication number
- AR122323A1 AR122323A1 ARP200102884A ARP200102884A AR122323A1 AR 122323 A1 AR122323 A1 AR 122323A1 AR P200102884 A ARP200102884 A AR P200102884A AR P200102884 A ARP200102884 A AR P200102884A AR 122323 A1 AR122323 A1 AR 122323A1
- Authority
- AR
- Argentina
- Prior art keywords
- particle size
- cocrystal
- niclosamide
- composition
- range
- Prior art date
Links
- 229960001920 niclosamide Drugs 0.000 title abstract 2
- -1 NICLOSAMIDE COMPOUND Chemical class 0.000 title 1
- 239000002245 particle Substances 0.000 abstract 3
- RJMUSRYZPJIFPJ-UHFFFAOYSA-N niclosamide Chemical class OC1=CC=C(Cl)C=C1C(=O)NC1=CC=C([N+]([O-])=O)C=C1Cl RJMUSRYZPJIFPJ-UHFFFAOYSA-N 0.000 abstract 2
- 239000013078 crystal Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
- C07C235/58—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring with carbon atoms of carboxamide groups and singly-bound oxygen atoms, bound in ortho-position to carbon atoms of the same non-condensed six-membered aromatic ring
- C07C235/64—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring with carbon atoms of carboxamide groups and singly-bound oxygen atoms, bound in ortho-position to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0031—Rectum, anus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pain & Pain Management (AREA)
- Otolaryngology (AREA)
- Pulmonology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962923290P | 2019-10-18 | 2019-10-18 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR122323A1 true AR122323A1 (es) | 2022-08-31 |
Family
ID=75492817
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP200102884A AR122323A1 (es) | 2019-10-18 | 2020-10-19 | Compuesto de niclosamida, composición que lo comprende y cocristal |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20210114973A1 (OSRAM) |
| EP (1) | EP4045480A4 (OSRAM) |
| JP (1) | JP2022553934A (OSRAM) |
| KR (1) | KR20240039083A (OSRAM) |
| CN (1) | CN117597327A (OSRAM) |
| AR (1) | AR122323A1 (OSRAM) |
| CA (1) | CA3157861A1 (OSRAM) |
| TW (1) | TW202128610A (OSRAM) |
| WO (1) | WO2021076922A1 (OSRAM) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2017529393A (ja) | 2014-09-12 | 2017-10-05 | アンティバイオティクス エーピーエスＡｎｔｉｂｉｏｔｘ Ａｐｓ | ハロゲン化サリチルアニリドの抗菌用途 |
| GB201509326D0 (en) | 2015-05-29 | 2015-07-15 | Antibio Tx Aps | Novel use |
| AU2016315852B2 (en) | 2015-09-01 | 2023-06-15 | First Wave Bio, Inc. | Methods and compositions for treating conditions associated with an abnormal inflammatory responses |
| GB201604484D0 (en) | 2016-03-16 | 2016-04-27 | Antibiotx Aps And Københavns Uni University Of Copenhagen | Topical antibacterial compositions |
| US11419834B2 (en) | 2019-02-25 | 2022-08-23 | Rhode Island Hospital | Methods for treating diseases or infections caused by or associated with H. pylori using a halogenated salicylanilide |
| US20230107927A1 (en) * | 2020-02-28 | 2023-04-06 | First Wave Bio, Inc. | Methods of treating iatrogenic autoimmune colitis |
| US10980756B1 (en) | 2020-03-16 | 2021-04-20 | First Wave Bio, Inc. | Methods of treatment |
| US11045434B1 (en) | 2020-04-01 | 2021-06-29 | UNION therapeutics A/S | Niclosamide formulations for treating disease |
| US12240813B2 (en) | 2020-05-19 | 2025-03-04 | Cybin Irl Limited | Deuterated tryptamine derivatives and methods of use |
| CN113768937B (zh) * | 2021-11-15 | 2022-04-08 | 恒翼生物医药科技(上海)有限公司 | 用于降低尿酸水平的化合物 |
| GB202301306D0 (en) * | 2023-01-30 | 2023-03-15 | Ucl Business Ltd | Treatment of granulomatous disease |
| CN117357523A (zh) * | 2023-10-25 | 2024-01-09 | 澳门大学 | 利拉萘酯在制备预防和治疗肺纤维化药物中的用途 |
| CN117466786A (zh) * | 2023-12-25 | 2024-01-30 | 湖南一格制药有限公司 | 盐酸戊乙奎醚杂质及其制备方法 |
| WO2025207484A1 (en) * | 2024-03-25 | 2025-10-02 | Merveille.Ai | Use of aprepitant and cyclic dipeptide for weight control |
| CN118649135B (zh) * | 2024-07-18 | 2024-12-10 | 广东药科大学 | 一种缓解高尿酸血症肾病进程的药物制剂及其制备方法 |
| CN119525016B (zh) * | 2024-12-24 | 2026-04-07 | 中国矿业大学 | 一种组合捕收剂及其在钾长石反浮选脱硅中的应用 |
| CN119431243B (zh) * | 2025-01-09 | 2025-06-10 | 万邦德制药集团有限公司 | 一种氘代石杉碱甲化合物或其药学上可接受的盐及其制备方法和应用 |
| CN119841970B (zh) * | 2025-01-23 | 2026-02-27 | 集美大学 | 一种具有抗炎活性的乙酰化卡拉胶及其制备方法和应用 |
| CN121406752A (zh) * | 2025-12-26 | 2026-01-27 | 圣湘生物科技股份有限公司 | 粘性生物样本的液化组合产品、核酸检测试剂盒及其应用 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2557615C2 (de) * | 1975-12-20 | 1985-08-14 | Bayer Ag, 5090 Leverkusen | Neue Niclosamid-Suspensionsformulierungen |
| NZ223200A (en) * | 1988-01-15 | 1989-01-06 | Ancare Distributors | Anthelmintic compositions containing 2',5-dicloro-4'-nitrosalicylanilide and non aqueous carrier |
| AU2003249244A1 (en) * | 2002-07-15 | 2004-02-02 | Combinatorx, Incorporated | Methods for the treatment of neoplasms |
| CN1546919A (zh) * | 2003-07-13 | 2004-11-17 | 叶声羽 | 桑拿浴房 |
| CN1626506A (zh) * | 2004-08-10 | 2005-06-15 | 李志良 | 高纯度、高收率氯硝柳胺的制备 |
| EP2123626A1 (en) * | 2008-05-21 | 2009-11-25 | Laboratorios del Dr. Esteve S.A. | Co-crystals of duloxetine and co-crystal formers for the treatment of pain |
| CN103751854B (zh) * | 2014-01-20 | 2015-08-26 | 瞿介明 | 抗菌医用导管 |
| AU2016315852B2 (en) * | 2015-09-01 | 2023-06-15 | First Wave Bio, Inc. | Methods and compositions for treating conditions associated with an abnormal inflammatory responses |
| EP3168211A1 (en) * | 2015-11-10 | 2017-05-17 | Westfälische Wilhelms-Universität Münster | Pharmaceutical co-crystals of niclosamide |
-
2020
- 2020-04-07 US US16/842,695 patent/US20210114973A1/en not_active Abandoned
- 2020-10-16 CA CA3157861A patent/CA3157861A1/en active Pending
- 2020-10-16 WO PCT/US2020/056027 patent/WO2021076922A1/en not_active Ceased
- 2020-10-16 JP JP2022522825A patent/JP2022553934A/ja active Pending
- 2020-10-16 CN CN202080088987.0A patent/CN117597327A/zh active Pending
- 2020-10-16 KR KR1020227016634A patent/KR20240039083A/ko not_active Ceased
- 2020-10-16 TW TW109136022A patent/TW202128610A/zh unknown
- 2020-10-16 EP EP20877454.7A patent/EP4045480A4/en not_active Withdrawn
- 2020-10-19 AR ARP200102884A patent/AR122323A1/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| WO2021076922A1 (en) | 2021-04-22 |
| US20210114973A1 (en) | 2021-04-22 |
| JP2022553934A (ja) | 2022-12-27 |
| KR20240039083A (ko) | 2024-03-26 |
| EP4045480A4 (en) | 2023-11-22 |
| CA3157861A1 (en) | 2021-04-22 |
| CN117597327A (zh) | 2024-02-23 |
| EP4045480A1 (en) | 2022-08-24 |
| TW202128610A (zh) | 2021-08-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UY38186A (es) | Sal sódica de n-((1,2,3,5,6,7-hexahidro-s-indacen-4-il)carbamoil)-1-isopropil-1h-pirazol-3-sulfonamida | |
| MX2020007947A (es) | Inhibidores de erbb/btk. | |
| DOP2020000102A (es) | Compuestos útiles para inhibir a cdk7 | |
| CL2022003360A1 (es) | Benzofurano, benzopirrol, benzotiofeno sustituidos y otros inhibidores del complemento estructuralmente relacionados (divisional de la solicitud 202002578) | |
| UY38425A (es) | Procesos novedosos para preparar n-((1,2,3,5,6,7-hexahidro-s-indacen-4-il)carbamoil)-1- isopropil-1h-pirazol-3-sulfonamida y sales de éste | |
| MX2022014864A (es) | Compuestos de bisamida que activan el sarcomero y sus usos. | |
| CL2019003610A1 (es) | Un esteroide 19 nor-c21-n-pirazolilo c3,3-disustituido cristalino. (divisional solicitud 201900477). | |
| MX2020011868A (es) | Inhibidores de los receptores erbb. | |
| ES3063891T3 (en) | Methods of reducing the risk of cardiovascular events in a subject | |
| CL2020001752A1 (es) | Derivado de oxi-fluoropiperidina como inhibidor de quinasa. | |
| ECSP20035222A (es) | Derivado de amino-fluoropiperidina como inhibidor de quinasa | |
| MX391414B (es) | Compuesto novedoso de bifenilo o sal del mismo. | |
| CY1126067T1 (el) | Συντηγμενες πυρρολινες που δρουν σαν ειδικοι για ουβικιτινη αναστολεις πρωτεασης 30 (usp30) | |
| AR053162A1 (es) | Compuesto 5 - oxo - pirrolidin sustituido, composicion farmaceutica que lo comprende y su uso para preparar un medicamento para el tratamiento del glaucoma. | |
| MA43518B1 (fr) | 3-azabicyclo[3.1.0]hexanes substitués servant d'inhibiteurs de cétohexokinase | |
| CL2020003101A1 (es) | Sales de sepiapterina farmacéuticamente aceptables. | |
| AR102973A1 (es) | Uso del compuesto 3,5-dihidroxi-4-isopropil-trans-estilbeno para la preparación de una composición farmacéutica, dicho compuesto y composición farmacéutica que lo comprende | |
| MX2021000093A (es) | Antagonistas del receptor de tipo toll 7/8 (tlr7/8) y usos de los mismos. | |
| MX2021006951A (es) | Formas cristalinas y formas de sal de un inhibidor de cinasa. | |
| MX2019008302A (es) | Inhibidores biciclicos de histona desacetilasa. | |
| MX2018003930A (es) | Inhibidores de calicreína plasmática humana. | |
| MX2021007201A (es) | Producto estable con esta?o para el cuidado oral. | |
| EP4074699A4 (en) | Compound as cyclin-dependent kinase 9 inhibitor and use thereof | |
| MX2019007239A (es) | Nueva formulacion que comprende un derivado de bencimidazol. | |
| MX2024015245A (es) | Compuestos utiles como moduladores de la autofagia mediada por chaperonas |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |